American Century Companies Inc. Has $3.34 Million Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

American Century Companies Inc. boosted its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 11.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 261,802 shares of the biopharmaceutical company’s stock after buying an additional 26,135 shares during the quarter. American Century Companies Inc.’s holdings in Dynavax Technologies were worth $3,343,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in DVAX. Smartleaf Asset Management LLC boosted its holdings in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at $71,000. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 1,076 shares during the period. Finally, KBC Group NV raised its stake in Dynavax Technologies by 68.7% during the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 2,857 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $12.65 on Monday. The company has a market cap of $1.57 billion, a P/E ratio of 70.28 and a beta of 1.26. The company has a fifty day simple moving average of $13.37 and a 200 day simple moving average of $12.56. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DVAX shares. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.